Numerous clinical trials are under way to evaluate therapeutic approaches to stop the progression of Alzheimer's disease (AD).
Alzheimer's Disease
AD is a fatal and devastating disorder characterized by progressive memory loss and severe cognitive deficits. AD has two pathological hallmarks: amyloid β (Aβ) plaques, derived from amyloid precursor protein, and neurofibrillary tangles, consisting of hyperphosphorylated tau protein. Tau protein is a microtubule-associated protein (MAP) responsible for cytoskeletal stability. It is implicated in cellular plasticity, migration, division, regulation of the cell cycle, and neuronal differentiation. Neurofibrillary tangles are accumulations of hyperphosphorylated tau that are well-correlated with cognitive deficits, brain atrophy, and neuronal loss in some brain regions.
Early-onset and familial forms of AD are caused by mutations in amyloid precursor protein or presenilin-1 or presenilin-2 proteins, resulting in overproduction of fibrillogenic Aβ species. Most cases (>95%), however, are sporadic late-onset AD not associated with mutations affecting Aβ metabolism. Therapies against Aβ have been forerunners in the field and provide an accurate view of the problems associated with developing an effective therapy. Data from phase I trial immunization, for example, showed clearance of Aβ plaques; however, neurofibrillary tangles and cognitive scores were not significantly changed. The hippocampus has a vital role in higher cognition. 7 While synaptic plasticity is thought to be the main structural change corresponding to cognitive function, ongoing neurogenesis is a novel and unique form of structural plasticity. New neurons generated in the subgranular zone form granule cells in the dentate gyrus of the hippocampus and are thought to have a rather limited input into the adult hippocampus on a short timescale. While the number of new neurons incorporated in the hippocampus may be quite low during aging, adult neurogenesis represents potential for adaptation. This has been described previously as the neurogenic reserve hypothesis: neurogenesis is a special type of brain plasticity that, when the hippocampus is actively engaged, allows for adaptation and resistance to accumulated deleterious insults. 8 Many adult-generated cells die within the first few weeks 9,10 due to selection determined by local neuronal activity and trophic support.
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Significant proportions of the newborn cells, however, eventually differentiate into fully functional neurons. 12 Neurogenesis has a significant role in hippocampal learning and appears to be required for the behavioral effects of antidepressants. 13, 14 Recent studies show further that neurogenesis may also occur outside the classical neurogenic niches; rare neurogenesis has been reported in the cortex, amygdala, hypothalamus, and substantia nigra, [15] [16] [17] [18] notably often in response to insult. Ischemia/reperfusion in the striatum can recruit new neurons from glial precursors in closely related brain regions such as the subventricular zone. 19, 20 Neurogenesis has also been reported after hippocampal or cortical damage from excitotoxic, ischemic, or epileptic events. [21] [22] [23] [24] [25] Interestingly, hypoxia-inducible expression of brain-derived neurotrophic factor, insulin-like growth factor 1, fibroblast growth factor 2, and vascular endothelial growth factor [26] [27] [28] are known stimulators of adult neurogenesis. 
Neurogenesis in the Alzheimer's Brain
A limited number of studies have examined post mortem human brain tissue using various immunocytochemical markers of neurogenesis. These studies have produced varying results, but collectively they provide crucial evidence. One report describes increases doublecortin, a marker of immature neurons, in a cohort of senile AD cases, suggesting that neurogenesis is increased in AD. 44 Doublecortin is a MAP linked with migrating neuroblasts, 45, 46 but has additionally been found to be very sensitive to degradation during post mortem delay, 42 and additional studies indicate that it may also be expressed by astrocytes under pathological conditions. 47 A study in a younger cohort of pre-senile patients did not replicate these results, finding that doublecortin expression was present in a minority of cases. 42 Significant increases in proliferation have been observed; however, these observations are non-specific for ongoing neurogenesis: proliferating Ki-67
antigen-positive cells were found in AD, but were not observed exclusively in the granule cell layer. 42 Other investigators found that expression of the mature neuronal markers, MAP isoforms MAP2a and b, were found to be decreased in AD dentate gyrus, whereas total MAP2, including expression of the immature MAP2c isoform, was less affected. This may suggest that new cells in the AD dentate gyrus do not become mature neurons, although proliferation is increased. 
Future Directions
To better understand disease progression and underlying mechanisms, various transgenic mouse lines have been developed expressing the ADrelated proteins amyloid precursor protein, presenilin 1, and/or tau. 49, 50 These models recapitulate various aspects of AD and frontal temporal lobe dementia and are inherently useful for understanding the timing of neurogenetic changes in AD progression. Such studies have so far produced conflicting results showing increases, 51 non-significant changes, 52 and decreases 53 in hippocampal neurogenesis in mouse models that depend, in part, on methodological differences in markers for neurogenesis and the age of the animals. Additional studies have also
shown that tau expression is linked to differences in neurogenesis. 54 For reviews, see Thompson et al. 55 and Kuhn et al.
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Conclusions
AD is characterized by cognitive deficits and progressive memory loss.
In addition to neuropathology in various brain regions, the hippocampus is particularly affected. Stem cells in the SGZ of the dentate gyrus produce new neurons that have acute and long-term consequences for
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